Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial Meeting Abstract

  

Authors:	Eskander, R.; Sill, M.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M.; Cantuaria, G.; Girda, E.; Mathews, C.; Kavecansky, J.; Leath, C.; Gien, L.; Hinchcliff, E.; Lele, S.; Landrum, L.; Backes, F.; O'Cearbhaill, R.; Liu, R.; Hill, E.; Thaker, P. H.; John, V.; Powell, M.; Aghajanian, C.
Abstract Title:	Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial
Meeting Title:	Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer
Journal Title:	Gynecologic Oncology
Volume:	190
Issue:	Suppl. 1
Meeting Dates:	2024 Mar 15-18
Meeting Location:	San Deigo, CA
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2024-11-01
Start Page:	S5
Language:	English
ACCESSION:	WOS:001330731400006
DOI:	10.1016/j.ygyno.2024.07.015
PROVIDER:	wos
Notes:	Meeting Abstract: 02 [LBA] -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/221712